Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FL vs TS-1/Irinotecan in Rectal Cancer
NCT01269216Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Oct 2008
- Primary completion
- Sep 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer (2 arms), sponsored by Yonsei University. Primary endpoint: pathologic complete response rate. Started Oct 2008; status: completed.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01269216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269216.